Abstract
Background: Advanced age remains one of the principal determinants of mortality in patients with acute myocardial infarction (AMI).
Hypothesis: The aim of this study was to determine the in‐hospital outcome of elderly (>75 years) patients with AMI who were admitted to hospitals participating in the national MITRA (Maximal Individual Therapy in Acute Myocardial Infarction) registry.
Methods: MITRA is a prospective, observational German multicenter registry investigating current treatment modalities for patients presenting with AMI. All patients with AMI admitted within 96 h of onset of symptoms were included in the MITRA registry. MITRA was started in June 1994 and ended in January 1997. This registry comprises 6,067 consecutive patients with a mean age of 65 ± 12 years, of whom 1,430 (17%) were aged > 75 years. Patients were compared with respect to patient characteristics, prehospital delays, early treatment strategies, and clinical outcome.
Results: In the elderly patient population, the prehospital delay was 210 min, which was significantly longer than that for younger patients (155 min, p = 0.001). Although the incidence of potential contraindications for the initiation of thrombolysis was almost equally distributed between the two age groups (8.7 vs. 8.2%, p = NS), elderly patients (> 75 years) received reperfusion therapy less frequently (35.9 vs. 64.6%) than younger patients. Mortality increased with advanced age and was 26.4% for all patients aged > 75 years. If reperfusion therapy was initiated, in‐hospital mortality was 21.8 versus 28.9% in patients aged > 75 years (p = 0.001) and 29.4 versus 38.5% in patients aged > 85 years (p = 0.001).
Conclusion: In this registry, elderly patients with AMI had a much higher in‐hospital mortality than that expected from randomized trials. In MITRA, the mortality reduction with reperfusion therapy was found to be highest in the very elderly patient population.
Keywords: acute myocardial infarction, early therapy, age
Full Text
The Full Text of this article is available as a PDF (594.0 KB).
References
- 1. Maggioni A, Maseri A, Fresco C, Franzoni MG, Mauri F, Santoro E, Togoni G: Age‐related increase in mortality among patients with first myocardial infarction treated with thrombolysis. N Engl J Med 1993; 329: 1442–1448 [DOI] [PubMed] [Google Scholar]
- 2. Guadagnoli E, Hauptman PJ, Ayanian JZ, Pashos CL, McNeil BJ, Cleary PD: Variation in the use of cardiac procedures after acute myocardial infarction. N Engl J Med 1995; 333: 573–578 [DOI] [PubMed] [Google Scholar]
- 3. Ketley D, Woods KL: Impact of clinical trials on clinical practice: Example of thrombolysis for acute myocardial infarction. Lancet 1993; 342: 891–894 [DOI] [PubMed] [Google Scholar]
- 4. Gruppo Italiano per lo Studiodella Streptochinasi nell'Infarto Miocardico (GISSI) : Long‐term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI study. Lancet 1987; 871–874 [PubMed]
- 5. ISIS‐2 : Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. Lancet 1988; 2: 349–360 [PubMed] [Google Scholar]
- 6. The GUSTO Angiographic Investigators : The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615–1622 [DOI] [PubMed] [Google Scholar]
- 7. Hjalmarson A, Elmfeldt D, Herlitz J, Holmberg S, Malek I, Nyberg G, Ryden L, Swedberg K, Vedin A, Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L, Wilhelmsson C: Effect on mortality of metoprolol in acute myocardial infarction, a double‐blind randomized trial. Lancet 1981; 2: 823–827 [DOI] [PubMed] [Google Scholar]
- 8. ISIS‐1 (First International Study on Infarct Survival) Collaborative Group : Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction. Lancet 1986; 2: 57–66 [PubMed] [Google Scholar]
- 9. Pfeffer MA, Braunwald E, Moyè LA, Basta L, Brown EJ Jr, Davis BR, Geltman EM, Goldman S, Flaker GC: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327: 669–677 [DOI] [PubMed] [Google Scholar]
- 10. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H: Effects of early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the Cooperative North Scandinavian Enalapril Survival Study II (Consensus II). N Engl J Med 1992; 327: 678–684 [DOI] [PubMed] [Google Scholar]
- 11. Rustige J, Schiele R, Burczyk U, Koch A, Gottwik M, Neuhaus L, Tebbe U, Uebis R, Senges J: The 60 Minutes Myocardial Infarction Project. Treatment and clinical outcome of patients with acute myocardial infarction in Germany. Eur Heart J 1997; 18: 1438–1446 [DOI] [PubMed] [Google Scholar]
- 12. The GUSTO Investigators : An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–682 [DOI] [PubMed] [Google Scholar]
- 13. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) : GISSI‐2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65–71 [PubMed] [Google Scholar]
- 14. ISIS‐3 (Third International Study of Infarct Survival) Collaborative Group : ISIS‐3: A randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and or aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected myocardial infarction. Lancet 1992; 339: 753–770 [PubMed] [Google Scholar]
- 15. The TIMI Study Group : Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989; 320: 618–627 [DOI] [PubMed] [Google Scholar]
- 16. Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers WJ: Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue‐type plasminogen activator) in patients with acute myocardial infarction. A report from the second National Registry of Myocardial Infarction (NRMI‐2): J Am Coll Cardiol 1998; 31: 1240–1250 [DOI] [PubMed] [Google Scholar]
- 17. Topol EJ, Califf RM: Thrombolytic therapy for elderly patients. N Engl J Med 1992; 327: 45–47 [DOI] [PubMed] [Google Scholar]
- 18. Boersma E, Maas ACP, Deckers JW, Simoons ML: Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996; 348: 771–775 [DOI] [PubMed] [Google Scholar]
- 19. Simoons ML, Boersma E, Maas ACP, Deckers JW: Management of myocardial infarction: The proper priorities. Eur Heart J 1998; 18: 896–899 [DOI] [PubMed] [Google Scholar]